Differential effects of polycyclic aromatic hydrocarbons on transactivation of AP-1 and NF-κB in mouse epidermal Cl41 cells

Molecular Carcinogenesis

Volumn 40, Issue 2, 2004, Pages 104-115

  Li, Jingxia ^a   Chen, Haobin ^a   Ke, Qingdong ^a   Feng, Zhaohui ^a   Tang, Moon Shong ^a   Liu, Bingci ^b   Amin, Shantu ^c   Costa, Max ^a   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

5 MCDE; B a PDE; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7,8 DIHYDROXYBENZO[A]PYRENE 9,10 OXIDE; BENZO[A]PYRENE; CARCINOGEN; CHRYSENE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 1A1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYCYCLIC AROMATIC HYDROCARBON; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPIDERMIS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; ANIMALS; BENZO(A)PYRENE; CARCINOGENS; CELLS, CULTURED; CHRYSENES; ENZYME INHIBITORS; EPIDERMIS; FLAVONOIDS; I-KAPPA B PROTEINS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHOSPHORYLATION; POLYCYCLIC HYDROCARBONS, AROMATIC; PYRIDINES; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1;

EID: 2942620289     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20020     Document Type: Article

References (66)

1. Bostrom CE, Gerde P, Hanberg A, et al. Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air. Environ Health Perspect 2002;110(Suppl 3):451-488.
2. Hecht SS, Bondinell WE, Hoffmann D. Chrysene and methylchrysenes: Presence in tobacco smoke and carcinogenicity. J Natl Cancer Inst 1974;53:1121-1133.
3. Hoffmann D, Djordjevic MV, Hoffmann I. The changing cigarette. Prev Med 1997;26:427-434.
4. Cosman M, de los Santos C, Fiala R, et al. Solution conformation of the major adduct between the carcinogen (+)-anti-benzo[a]pyrene diol epoxide and DNA. Proc Natl Acad Sci USA 1992;89:1914-1918.
5. IARC. Polynuclear aromatic compounds, Part 1. Volume 32. 1983. pp 66-67.
6. Amin S, Misra B, Braley J, Hecht SS. Comparative tumorigenicity in newborn mice of chrysene- and 5-alkylchrysene-1,2-diol-3,4-epoxides. Cancer Lett 1991;58:115-118.
7. You L, Wang D, Galati AJ, et al. Tumor multiplicity, DNA adducts and K-ras mutation pattern of 5-methylchrysene in strain A/J mouse lung. Carcinogenesis 1994;15:2613-2618.
8. Nesnow S, Mass MJ, Ross JA, et al. Lung tumorigenic interactions in strain A/J mice of five environmental polycyclic aromatic hydrocarbons. Environ Health Perspect 1998; 106(Suppl 6):1337-1346.
9. Bernelot-Moens C, Glickman BW, Gordon AJ. Induction of specific frameshift and base substitution events by benzo[a]pyrene diol epoxide in excision-repair-deficient Escherichia coli. Carcinogenesis 1990;11:781-785.
10. Merimsky O, Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998;16:585-588.
11. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-811.
12. Levin W, Wood AW, Wislocki PG, et al. Carcinogenicity of benzo-ring derivatives of benzo(a)pyrene on mouse skin. Cancer Res 1977;37:3356-3361.
13. Buening MK, Wislocki PG, Levin W, et al. Tumorigenicity of the optical enantiomers of the diastereomeric. Proc Natl Acad Sci USA 1978;75:5358-5361.
14. Glatt H, Wameling C, Elsberg S, et al. Genotoxicity characteristics of reverse diol-epoxides of chrysene. Carcinogenesis 1993;14:11-19.
15. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-432.
16. Pitot HC III, Dragon YP. Chemical carcinogenesis. In: Klaassen CD, editor. Casarett & Doull's toxicology: The basic science of poisons, 5th edition. New York: McGraw-Hill, Health Professions Division; 1996. pp 201-267.
17. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 2001;159:387-397.
18. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
19. Huang C, Ma WY, Ryan CA, Dong Z. Proteinase inhibitors I and II from potatoes specifically block UV-induced activator protein-1 activation through a pathway that is independent of extracellular signal-regulated kinases, c-Jun N-terminal kinases, and P38 kinase. Proc Natl Acad Sci USA 1997;94: 11957-11962.
20. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase. Cancer Res 1997;57:2873-2878.
21. Huang C, Chen N, Ma WY, Dong Z. Vanadium induces AP-1- and NFkappB-dependent transcription activity. Int J Oncol 1998;13:711-715.
22. Huang C, Li J, Ma WY, Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 1999;274:29672-29676.
23. Eltom SE, Zhang L, Jefcoate CR. Regulation of cytochrome P-450 (CYP) 1B1 in mouse Hepa-1 variant cell lines: A possible role for aryl hydrocarbon receptor nuclear translocator (ARNT) as a suppressor of CYP1B1 gene expression. Mol Pharmacol 1999;55:594-604.
24. Yang HS, Knies JL, Stark C, Colburn NH. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003;22:3712-3720.
25. Jyonouchi H, Sun S, Iijima K, Wang M, Hecht SS. Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Carcinogenesis 1999;20: 139-145.
26. Chang TK, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994;311:437-442.
27. Puntarulo S, Cederbaum AI. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic Biol Med 1998;24:1324-1330.
28. Sapone A, Affatato A, Canistro D, et al. Induction and suppression of cytochrome P450 isoenzymes and generation of oxygen radicals by procymidone in liver, kidney and lung of CD1 mice. Mutat Res 2003;527:67-80.
29. Lin SJ, Shyue SK, Liu PL, et al. Adenovirus-mediated overexpression of catalase attenuates oxLDL-induced apoptosis in human aortic endothelial cells via AP-1 and C-Jun N-terminal kinase/extracellular signal-regulated kinase mitogen-activated protein kinase pathways. J Mol Cell Cardiol 2004;36: 129-139.
30. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
31. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996;14:649-683.
32. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997;57:3569-3576.
33. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 1996;13: 1367-1378.
34. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996;87:13-20.
35. Galang CK, Garcia-Ramirez J, Solski PA, et al. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J Biol Chem 1996;271: 7992-7998.
36. Yan Z, Subbaramaiah K, Camilli T, et al. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB. J Biol Chem 2000;275:4949-4955.
37. Parrish AR, Fisher R, Bral CM, et al. Benzo(a)pyrene-induced alterations in growth-related gene expression and signaling in precision-cut adult rat liver and kidney slices. Toxicol Appl Pharmacol 1998;152:302-308.
38. Manna SK, Aggarwal BB. Wortmannin inhibits activation of nuclear transcription factors NF-kappaB and activated protein-1 induced by lipopolysaccharide and phorbol ester. FEBS Lett 2000;473:113-118.
39. Friedewald WFRP. The initiation and promoting elements in tumor production. J Exp Med 1944;80:101-126.
40. Tannheimer SL, Ethier SP, Caldwell KK, Burchiel SW. Benzo[a]pyrene- and TCDD-induced alterations in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line. Carcinogenesis 1998;19:1291-1297.
41. Banerjee R, Caruccio L, Zhang YJ, McKercher S, Santella RM. Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology 2000;32:367-374.
42. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-569.
43. Hsu TC, Nair R, Tulsian P, et al. Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. Cancer Res 2001;61:4160-4168.
44. Smith MJ, Prochownik EV. Inhibition of c-jun causes reversible proliferative arrest and withdrawal from the cell cycle. Blood 1992;79:2107-2115.
45. Kovary K, Bravo R. The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 1991;11:4466-4472.
46. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994;91:609-613.
47. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-569.
48. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 1997;94:5826-5830.
49. Huang C, Ma WY, Young MR, Colburn N, Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci USA 1998;95:156-161.
50. Watts RG, Huang C, Young MR, et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-3498.
51. Dong Z, Watts RG, Sun Y, Zhan SN, Colburn NH. Progressive elevation of AP-1 activity during preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Int J Oncol 1995;7:359-364.
52. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-2400.
53. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 1999;18: 7423-7431.
54. Budunova IV, Kowalczyk D, Perez P, Yao YJ, Jorca no JL, Slaga TJ. Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis. Oncogene 2003;22:3279-3287.
55. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001;61:4901-4909.
56. Yang J, Xu Y, Zhu C, Hagan MK, Lawley T, Offermann MK. Regulation of adhesion molecule expression in Kaposi's sarcoma cells. J Immunol 1994;152:361-373.
57. Seitz CS, Lin Q, Deng H, Khavari PA. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 1998;95:2307-2312.
58. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 1999;59:3299-3303.
59. van Hogerlinden M, Auer G, Toftgard R. Inhibition of Rel/nuclear factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene 2002;21: 4969-4977.
60. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
61. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-10128.
62. Ichijo H. From receptors to stress-activated MAP kinases. Oncogene 1999;18:6087-6093.
63. Collins LR, Minden A, Karin M, Brown JH. Galpha12 stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac. J Biol Chem 1996;271:17349-17353.
64. English J, Pearson G, Wilsbacher J, et al. Newinsights intothe control of MAP kinase pathways. Exp Cell Res 1999;253: 255-270.
65. Huang C, Huang Y, Li J, et al. Inhibition of benzo(a)pyrene diol-epoxide-induced transactivation of activated protein 1 and nuclear factor kappaB by black raspberry extracts. Cancer Res 2002;62:6857-6863.
66. Li J, Tang S, Liu B, Shi X, Huang C. A critical role of PI-3K/Akt/JNKs pathway in benzo(a)pyrene diol-epoxide (BPDE)-induced AP-1 transactivation in mouse epidermal cells. Oncogene 2004; in press.